Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839501 · ClinicalTrials.gov registry record · Phase 1
Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome
A Phase 1 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00839501 is a Phase 1 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 3 participants.
The verdict
NCT00839501, a Phase 1 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Andersen-Tawil Syndrome (ATS) is a rare genetic disorder that causes episodes of muscle weakness, potentially life-threatening changes in heart rhythm, and skeletal developmental abnormalities. The cause of some ATS cases remains unknown, and no specific treatments have been established. The purpose of this study is to determine whether potassium supplements and/or the medication acetazolamide affect the duration of muscle weakness and heart rhythm abnormalities in people with ATS.
Interventions
- DRUG Acetazolamide
- DIETARY_SUPPLEMENT Potassium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00839501
The ClinicalTrials.gov registry entry for NCT00839501 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acetazolamide is the first listed.
NCT00839501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00839501 about?
NCT00839501 is a clinical study titled "Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome". Andersen-Tawil Syndrome (ATS) is a rare genetic disorder that causes episodes of muscle weakness, potentially life-threatening changes in heart rhythm, and skeletal developmental abnormalities. The cause of some ATS cases remains unknown, and no specific treatments have been established. The purpose...
What is the current status of trial NCT00839501?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2008-12. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00839501?
The interventions under investigation include: Acetazolamide (DRUG), Potassium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00839501?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.